Acrivon Therapeutics, Inc. (ACRV) AI Stock Analysis

• Market Cap: $64.32M
• Dividend Yield: N/A
• Average Volume (3M): 996.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: N/A
• EPS Growth: 21.17%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 31,555,126
• 10 Day Avg. Volume: 442,853
• 30 Day Avg. Volume: 996,436
• PEG Ratio: 0.31
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.42
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.18
• 1Y Price Target: $13.50
• Price Target Upside: 694.12% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.93
• Revenue Forecast (FY): $1.31M

• Rating: 49 Neutral
• Price Target: $1.50 ▼(-11.76% Downside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

Score is held down primarily by weak financial performance (no revenue, sizable losses, and heavy cash burn), with additional drag from a mostly bearish longer-term technical trend. Positive recent corporate updates and cash runway provide a partial offset, but valuation metrics offer limited support given negative earnings and no dividend.

Positive Factors

High ACR-368 efficacy in serous endometrial cancer

Robust confirmed responses in serous endometrial cancer materially strengthen Acrivon’s registrational case for ACR-368. Durable clinical efficacy in a high-unmet-need subgroup raises probability of accelerated approval and sustainable commercial opportunity in a focused oncology niche.

Proprietary biomarker strategy and CLIA lab

Owning a CLIA-certified lab and a prospective OncoSignature patient selection approach increases trial efficiency and predictive enrichment. This structural capability can lower development risk, support companion-diagnostic validation, and provide a durable competitive advantage in precision oncology.

Adequate near-term cash runway

A cash balance covering operations into Q2 2027 gives management runway to complete planned Phase 2b cohorts, expand EU enrollment and operationalize the CLIA lab. This reduces immediate financing pressure and enables execution of key value-driving catalysts over the next 12–15 months.

Negative Factors

Persistent heavy cash burn

Consistently deep negative operating and free cash flow shows the business is cash-consuming and dependent on external financing. Over time this elevates dilution risk, constrains resource allocation, and forces prioritization of programs, potentially delaying broader pipeline advancement.

Eroding equity base

Material decline in shareholder equity reflects cumulative losses and reduces the company’s balance sheet cushion. A smaller equity base limits financial flexibility to withstand trial setbacks, increases reliance on capital markets, and can magnify dilution when raising funding for continued development.

Concentration of value in early-stage programs

As a development-stage biotech with no revenue, Acrivon’s long-term prospects are highly contingent on binary clinical and regulatory outcomes—primarily ACR-368. Program-level failures or regulatory setbacks would materially impair value, as other candidates remain early and carry typical discovery/clinical risk.

Acrivon Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

How the Company Makes Money

null

Acrivon Therapeutics, Inc. Financial Statement Overview

Summary

Development-stage profile with no revenue and large, persistent losses plus deep negative operating cash flow/free cash flow (TTM OCF about -$63.7M; TTM FCF about -$65.3M) that increase financing/dilution risk. Offsetting strength is low leverage (modest debt) and still-meaningful equity, but equity has eroded with ongoing losses.

Income Statement

Across the period and in TTM (Trailing-Twelve-Months), the company reports no revenue and consistently large operating losses. Losses have expanded materially versus 2022 (EBIT roughly -$32.7M) to 2024 (EBIT roughly -$89.2M), with TTM remaining deeply negative (EBIT roughly -$84.1M). Net losses are also sizable and persistent (TTM net income roughly -$77.9M), reflecting a business still in heavy investment mode with limited current earnings visibility.

Balance Sheet

The balance sheet shows low leverage, with total debt modest at roughly $2.7M in TTM (Trailing-Twelve-Months) and a low debt-to-equity ratio (~0.02–0.04 in recent years). Equity is positive and substantial in 2022–TTM (TTM equity roughly $112.5M), supporting financial flexibility. The key weakness is ongoing value erosion from losses: equity declined from roughly $176.8M (2024) to roughly $112.5M (TTM), and returns on equity are meaningfully negative in recent years, indicating continued burn against the capital base.

Cash Flow

Cash generation remains a major headwind, with operating cash flow negative every year and still deeply negative in TTM (Trailing-Twelve-Months) at roughly -$63.7M. Free cash flow is also consistently negative (TTM roughly -$65.3M) and deteriorated versus 2024 (free cash flow growth is sharply negative in TTM), implying an accelerating cash burn profile. A modest positive is that free cash flow roughly tracks net loss (TTM free cash flow to net income ~1.03), suggesting losses are largely cash-backed rather than driven by unusually large non-cash items.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-1.01M	-536.00K	0.00	0.00
EBITDA	-84.11M	-79.55M	-59.85M	-32.29M	-16.15M
Net Income	-77.91M	-80.56M	-60.39M	-31.17M	-16.24M
Balance Sheet
Total Assets	129.72M	196.59M	138.26M	181.23M	106.59M
Cash, Cash Equivalents and Short-Term Investments	118.58M	179.48M	127.46M	127.75M	99.60M
Total Debt	2.71M	3.65M	4.64M	4.96M	5.63M
Total Liabilities	17.20M	19.80M	17.07M	10.75M	130.40M
Stockholders Equity	112.52M	176.79M	121.19M	170.47M	-23.81M
Cash Flow
Free Cash Flow	-65.33M	-68.44M	-43.93M	-32.28M	-14.22M
Operating Cash Flow	-63.66M	-65.67M	-42.64M	-30.12M	-13.98M
Investing Cash Flow	66.10M	-51.77M	50.72M	-141.68M	-238.00K
Financing Cash Flow	-749.00K	121.03M	-1.55M	101.71M	112.22M

Acrivon Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Neutral. The current price of 1.7 is above the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.74, and below the 200-day MA of 1.74, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 58.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACRV.

Acrivon Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMP	52 Neutral	$259.60M	-2.32	-162.49%	―	―	5.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$64.32M	-1.19	-53.71%	―	―	21.17%
ALGS	42 Neutral	$42.14M	-1.22	-141.82%	―	-55.88%	6.14%

Acrivon Therapeutics, Inc. Corporate Events

Acrivon Highlights Positive ACR-368 Data and 2025 Results

On March 19, 2026, Acrivon Therapeutics reported fourth quarter and full-year 2025 results, highlighting progress in its registrational-intent Phase 2b trial of ACR-368 in endometrial cancer, including a 52% confirmed overall response rate in serous endometrial cancer versus 22% in non-serous disease. The company has completed exploratory Arm 2 using ACR-368 plus ultra low-dose gemcitabine in biomarker-negative patients, initiated Arm 3 in all-comer serous endometrial cancer, and plans to launch Arm 4 testing ACR-368 monotherapy in biomarker-unselected serous endometrial cancer in 2026, while early Phase 1 data for ACR-2316 show encouraging activity in lung cancer, and cash of $118.6 million as of December 31, 2025 is expected to fund operations into the second quarter of 2027.

Acrivon also advanced its broader precision medicine infrastructure by launching a CLIA-certified laboratory for patient testing and companion diagnostic development, and nominating ACR-6840 as an internally discovered oral CDK11 inhibitor for future clinical development. Financially, the company narrowed its net loss to $19.0 million for the fourth quarter and $77.9 million for 2025, with lower research and development and general and administrative expenses year over year, underscoring disciplined spending as it seeks to strengthen its position in high-unmet-need oncology indications such as serous endometrial cancer and AP3-prioritized solid tumors.

The most recent analyst rating on (ACRV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data

On February 27, 2026, Acrivon Therapeutics hosted a live, company-sponsored key opinion leader panel during the ESGO Congress in Copenhagen to discuss interim Phase 2b data from its registrational-intent ACR-368 trial in endometrial cancer. Experts reviewed the study’s biomarker-driven design using the OncoSignature test, which prospectively selects patients based on CHK1/2 dependency, and highlighted the drug’s potential to address significant unmet need in high-grade and serous endometrial carcinoma.

The interim data presented showed notable objective response rates in biomarker-positive patients treated with ACR-368, including higher responses in those with two or fewer prior lines of therapy and meaningful disease control in serous and non-serous subgroups. Safety findings indicated a manageable toxicity profile consistent with chemotherapy-like hematologic adverse events, suggesting ACR-368 could strengthen Acrivon’s position in advanced gynecologic oncology and may offer a new option for heavily pretreated endometrial cancer patients, particularly after platinum and immunotherapy failure.

The most recent analyst rating on (ACRV) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.

Acrivon Showcases Promising Phase 2b Oncology Data Update

On January 8, 2026, Acrivon Therapeutics hosted a corporate webcast and conference call to present updated clinical data for its lead oncology programs ACR-368 and ACR-2316, alongside broader AP3 pipeline developments. The company highlighted Phase 2b data from its ACR-368-201 (GOG-3082) trial in endometrial cancer, including an overall response rate of 39% for ACR-368 monotherapy in OncoSignature-positive patients and 26% for the ACR-368 plus ultra-low-dose gemcitabine combination, as well as particularly strong responses in biomarker-selected and serous endometrial cancer subgroups; these results, derived from non–QC’ed data as of December 4, 2025, support ACR-368’s registrational-intent pathway and reinforce Acrivon’s biomarker-driven strategy in a tumor type with significant unmet need, potentially strengthening its competitive positioning in precision oncology.

The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data

On January 8, 2026, Acrivon Therapeutics reported updated Phase 2b data for its CHK1/CHK2 inhibitor ACR-368 in endometrial cancer, with an interim analysis as of December 4, 2025 showing a 39% overall response rate in biomarker-positive monotherapy patients and a 44% rate in those with two or fewer prior lines of therapy; in the serous endometrial cancer subtype, confirmed response rates reached 67% in biomarker-positive patients and 52% across biomarker-positive and -negative subjects, prompting the company to refocus Arm 3 of the trial on serous patients with limited prior treatment and to expand this arm into more than 20 trial sites across Germany, Italy, France and Spain, with EU enrollment expected to begin in the first quarter of 2026 and overall Arm 3 enrollment completion targeted for the fourth quarter of 2026. The company also detailed progress in its broader pipeline, including initial Phase 1 results for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, where 33 patients treated as of December 22, 2025 showed favorable tolerability and tumor shrinkage in 9 of 20 evaluable subjects—including partial responses in endometrial cancer, small cell lung cancer and squamous non-small cell lung cancer—and the nomination of ACR-6840, an AP3-derived CDK11 inhibitor, as its next development candidate with an investigational new drug application planned for late 2026, underscoring Acrivon’s drive to build a differentiated, AP3-enabled precision oncology franchise.

The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.